During the previous
According to the
After facing persistent downward pressure on the stock throughout most of this year, with a low point of .0010, there has been a notable stabilization and recovery, with the stock now ranging between .0020 and .0030. Over the past few days, there has been a significant increase in trading volume, resulting in a 34% gain and 2.5 million shares traded yesterday. Similarly, Wednesday's trading saw a 15% gain with 6 million shares traded. While the company has been relatively quiet since April, the recent surge in volume and upward momentum suggests that updates may be on the horizon.
On
Furthermore, DNAX disclosed that it has decided not to proceed with the acquisition of
Following a period of relative silence, the most recent update from the company came in the form of a tweet on Twitter on 6/15, stating that "$DNAX regains OTC Markets Pink Current Information status." Notably, the stock experienced unusual trading volume that, reaching a high of +160% on 4 million shares traded.
Since that particular day, there has been a noticeable surge in interest, as evidenced by the past four consecutive days where trading volumes exceeded 3 million shares per day. Yesterday's trading session was particularly noteworthy, with a record-breaking 9 million shares traded and the stock reaching highs of over 100% at a price of .0037. This level of activity is quite remarkable, considering that the average daily volume for this ticker is typically below 500,000 shares. Additionally, with 56 million shares held at DTC and a market capitalization of 700k, this company exhibits promising potential for growth and further updates. It would be prudent to monitor this stock closely for potential upside opportunities.
At the core, their philosophy is the belief that they can achieve this by delivering innovative solutions that offer rapid and long-lasting pain relief for a wide range of ailments. Through their expertise, they can engineer user-friendly bioelectronics therapy devices that transmit a proprietary sequence of electrical signals. Over the past decade, their devices have consistently demonstrated high effectiveness, and they possess the technological capabilities to support their application in medical research.
On
Following the receipt of the net proceeds, the Registrant allocated the funds as follows for its previously announced and disclosed product, the "Wellness Pro Plus Infinity":
This particular stock, similar to others, has faced downward pressure throughout the majority of the year. However, it has recently found some stability around the low .0010 range. Notably, the past four trading days have witnessed a significant surge in trading activity and investor interest, resulting in price highs of .0019 and a closing price of .0016, reflecting an increase of nearly 20% just yesterday. Given this trading activity, it would be wise to keep an eye on this stock for potential updates from the company.
Despite the company not being very vocal, it has seemed to be a stock that has gained some interest. With a float of 50 million shares in the low .0010 range and a market capitalization of
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content.
CONTACT: CONTACT: Bigtimepennystocks.com
Editor: mail@bigtimepennystocks.com
.
(C) 2023 M2 COMMUNICATIONS, source